Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: A randomized, placebo-controlled and dose-finding study

Neurogastroenterology and Motility

Volumn 23, Issue 6, 2011, Pages

  Fukudo, S ^a   Hongo, M ^b   Kaneko, H ^c   Ueno, R ^d  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

^d Sucampo Pharmaceuticals Inc   (United States)

Author keywords

Chronic idiopathic constipation; Irritable bowel syndrome; Lubiprostone; Rome iii criteria; Type 2 chloride channel

Indexed keywords

CHLORIDE CHANNEL; LUBIPROSTONE; PLACEBO;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY TEMPERATURE; BODY WEIGHT; CONSTIPATION; CONTROLLED STUDY; DEFECATION HABIT; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; EPIGASTRIC PAIN; FEMALE; HEADACHE; HEART PALPITATION; HEARTBURN; HEMORRHOID; HUMAN; IMPETIGO; IRRITABLE COLON; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VERTIGO; VOMITING;

ADULT; ALPROSTADIL; ASIAN CONTINENTAL ANCESTRY GROUP; CHLORIDE CHANNELS; CONSTIPATION; DEFECATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME;

EID: 79955897225     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2011.01668.x     Document Type: Article

References (27)

1. Drossman DA, Li Z, Andruzzi E et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 1569-80.
2. Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001; 96: 3130-7.
3. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
4. Tariq SH. Constipation in long-term care. J Am Med Dir Assoc 2007; 8: 209-18.
5. Watanabe T, Nakaya N, Kurashima K, Kuriyama S, Tsubono Y, Tsuji I. Constipation, laxative use and risk of colorectal cancer: The Miyagi cohort study. Eur J Cancer 2004; 40: 2109-15.
6. Shinozaki M, Fukudo S, Hongo M et al. High prevalence of irritable bowel syndrome in medical outpatients in Japan. J Clin Gastroenterol 2008; 42: 1010-6.
7. Schiller LR, Dennis E, Toth G. Primary care physicians consider constipation as a severe and bothersome medical condition that negatively impacts patients' lives. Am J Gastroenterol 2004; 99: S234.
8. Schiller LR, Dennis E, Toth G. An Internet-based survey of the prevalence and symptom spectrum of chronic constipation. Am J Gastroenterol 2004; 99: S234.
9. Cuppoletti J, Malinowska DH, Tewari KP et al. SPI-0211 activates T84 cell chloride transport and recombinant human CIC-2 chloride currents. Am J Physiol Cell Physiol 2004; 287: C1173-83.
10. Ueno R, Osama H, Habe T, Engelke K, Patchen M. Oral SPI-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels. Gastroenterology 2004; 126(Suppl. 2): 298.
11. Camilleri M, Bharucha AE, Ueno R et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006; 290: G942-7.
12. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008; 103: 170-7.
13. Barish C, Drossman D, Johanson J, Ueno R. Efficacy and safety of lubiprostone in chronic constipation. Dig Dis Sci 2010; 55: 1090-7.
14. Drossman DA, Chey WD, Johanson JF et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29: 329-41.
15. Chang L, Toner BB, Fukudo S et al. Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology 2006; 130: 1435-46.
16. Gwee KA, Bak YT, Ghoshal UC et al. Asian consensus in irritable bowel syndrome. J Gastroenterol Hepatol 2010; 25: 1189-205.
17. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007; 25: 1351-61.
18. Ware JE Jr, Sherboume CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Car 1992; 30: 473-83.
19. Fukuhara S, Ware JE Jr, Kosinski M, Wada S, Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 1998; 51: 1045-53.
20. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 400-11.
21. Drossman DA, Patrick DL, Whitehead WE et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000; 95: 999-1007.
22. Kanazawa M, Drossman DA, Shinozaki M et al. Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J). BioPsychoSoc Med 2007; 1: 6. [epub].
23. Whitehead WE, Levy RL, Von Korff M et al. The usual medical care for irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20: 1305-15.
24. Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976; 63: 655-60.
25. Owen RT. Lubiprostone - a novel treatment for irritable bowel syndrome with constipation. Drugs Today (Barc) 2008; 44: 645-52.
26. Irvine EJ, Whitehead WE, Chey WD et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006; 130: 1538-51.
27. Creed F, Fernandes L, Guthrie E et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003; 124: 303-17.